Skip to content
BALCAO · LABORATORY ANALYTICAL INSTRUMENTS

Bioforce Nanosciences Holdings, Inc. BFNH

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$-1.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company BioForce Nanosciences Holdings, Inc. ("BioForce" or the "Company") was previously in the business of manufacturing nano-particular measurement devices and molecular printers, but due to a lack of profitability, the subsidiary of the company that owned that technology filed for bankruptcy. BioForce entered into the supplement business in or about 2015. BioForce currently markets its products through social media and telemarketing. BioForce Nanosciences Holdings, Inc. maintains an executive office in Virginia Beach, Virginia. The Company has three full time employees, Mr. Merle Ferguson, its Chairman, Mr. Richard Kaiser, its CFO and Secretary, and Mr. Steve Gagnon, Co-CEO.

Written from the business description in Bioforce Nanosciences Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 9-year series below
Revenue $ Net income $
FY2019 · Revenue 17775.0 · Net income -46538.0
10000.020000.0-25000.0-50000.0
2017202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2019 · Operating -261.8% · Net -261.8%
-200%-400%-600%
201720212025
ROE
FY2019 · ROE -120.7%
-100%-200%-300%
201720212025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks

Total assetsUSD 786.00
EquityUSD -618,543.00
CashUSD 786.00
Current ratio0.00×

Equity funds -78695% of total assets.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BFNH, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B◌◌◌◌◌◌0.00.00.0
Operating income $B−0.0−0.0◌◌◌◌−0.0−0.0−0.0
EBITDA $B◌◌◌◌◌◌◌◌◌
Income tax $B◌◌◌◌◌◌0.00.0◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.2−0.0−0.0−0.0
EPS, diluted $−0.04−0.02−0.02−0.02−0.02−9.720.000.000.00
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %——————−120.7−356.5−381.1
Shares out B0.030.030.030.030.030.030.020.080.08

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 36 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017. 10 checks were skipped: revenue is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityLaboratory Analytical Instruments
Listed onOTC market
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2017

Share this section

Download image